SCHEMBL4313197

SCHEMBL4313197

Cc1ccsc1C(=O)Nc1cc(CN2CCN(C)CC2)ccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.74
AURKB Q96GD4 7/20 0.74
FGFR1 P11362 2/20 0.44
FLT1 P17948 1/20 0.44
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
NTRK1 P04629 2/20 0.39
PDGFRB P09619 2/20 0.39
ABL1 P00519 1/20 0.39
CSF1R P07333 1/20 0.39
KIT P10721 1/20 0.39
PDGFRA P16234 1/20 0.39
NTRK3 Q16288 1/20 0.39
NTRK2 Q16620 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SUCNR1 Q9BXA5 1/20 0.39
MAP4K4 O95819 1/20 0.38
FLT3 P36888 1/20 0.38
DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313205 1.00 AURKA (0.74) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL4326126 0.95 AURKA (0.74) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL4326122 0.95 AURKA (0.74) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL4320834 0.94 AURKA (0.73) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL31872 0.94 AURKA (0.73) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL4320842 0.94 AURKA (0.73) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL4324732 0.93 AURKA (0.70) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL4313646 0.93 AURKA (0.72) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL14989352 0.93 AURKB (0.70) AURKAAURKBFGFR1FLT1CDK5
SCHEMBL4324741 0.93 AURKA (0.70) AURKAAURKBFGFR1FLT1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 EP claimed
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 CN claimed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US claimed
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 EP disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885FGFR1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.